We identified 507 patients with MBC and BMs with the following subtypes: HR+/HER2- (n = 184, 36.3%), HER2+ (n = 197, 38.9%), and triple negative breast cancer (TNBC; n = 126, 24.9%). This evidence concerns the gene HR and triple-negative breast carcinoma.